VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Annunziata on Olaparib and Cediranib Combination in Ovarian Cancer

Christina M. Annunziata, MD, PhD
Published: Tuesday, Mar 14, 2017



Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.

In the phase II setting, an initial signal of activity and safety will be investigated for each of the 4 arms, explains Annunziata. Currently, there are no data regarding these drugs in the platinum-resistant setting.

This study will then move on to the phase III setting to compare the combination with the standard of care.
 


Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.

In the phase II setting, an initial signal of activity and safety will be investigated for each of the 4 arms, explains Annunziata. Currently, there are no data regarding these drugs in the platinum-resistant setting.

This study will then move on to the phase III setting to compare the combination with the standard of care.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x